[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chest-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chest-pain":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,44,76,116,154,178,210,237,260,285,311,335,359,379,419,443,463,483,511,534,555,583,608,629,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100534526","vericiguat-in-patients-with-coronary-microvascular-dysfunction-causing-stable-chest-pain-v-com-100534526",false,"NCT06239974","Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)","Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)","Inclusion Criteria:\n\n1. Stable recurrent chest pain.\n2. 40 to 75 years old.\n3. Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (\\\u003C50% coronary artery stenosis or fractional flow reserve \\>0.8).\n4. Stress CMR MPR \\\u003C2.19 12 or Stress MBF \\\u003C2.19ml\u002Fg\u002Fmin 13.\n5. Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.\n\nExclusion Criteria:\n\n1. Systolic blood pressure \\\u003C100 mm Hg.\n2. Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil).\n3. Has known allergy or sensitivity to any soluble guanylate cyclase stimulator.\n4. On long-acting nitrates (eg. isosorbide mononitrate)\n5. Known cardiomyopathy, complex congenital heart disease, endocarditis or pericarditis.\n6. Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)) or coronary revascularization (coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) within 60 days prior to randomisation, or indication for coronary revascularization at time of randomisation.\n7. Has symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days prior to randomisation.\n8. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n9. Malignancy or other non-cardiac condition limiting life expectancy to \\\u003C3 years.\n10. Patient's with implanted devices which are not MRI compatible.","ALL","40 Years","75 Years",{"count":21,"type":22},94,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.",[28],"Chest Pain",[30],"Stress Cardiac Magnetic Resonance","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2024-09-01",{"date":39,"type":22},"2027-08-31",{"name":41,"class":42},"The University of Hong Kong","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100642257","contactless-ultrasound-data-acquisition-in-emergency-departments-to-discriminate-the-origin-of-dyspnea-and-chest-pain-100642257","NCT07653204","Contactless Ultrasound Data Acquisition in Emergency Departments to Discriminate the Origin of Dyspnea and Chest Pain","Prospective Study for Data Acquisition in Emergency Departments to Develop a Discrimination Algorithm for the Origin of Dyspnea and Chest Pain Using the ADx-One Medical Device","PAnDA-One","Inclusion Criteria:\n\n* Presentation to the emergency department for one or more of the following symptoms of less than 14 days' duration: acute non-traumatic dyspnea, or recent worsening of chronic dyspnea, or non-traumatic chest pain.\n* Patient able to sit on a chair or on the edge of the bed\n* Affiliation to national health insurance\n* Able to receive study information, understand the study, and provide written informed consent\n\nExclusion Criteria:\n\n* • Immediate need for life-saving intervention or clinical instability incompatible with study procedures.\n\n  * Shock or severe hemodynamic instability, for example systolic blood pressure \\\u003C90 mmHg for at least 30 minutes or associated signs of hypoperfusion.\n  * Altered mental status or any condition preventing provision of valid informed consent.\n  * Known cognitive impairment preventing informed consent.\n  * Transfer to another care site before the ADx-One acquisition can be performed.\n  * Known pregnancy\n  * Minor, legally protected adult, or person deprived of liberty.\n  * Participation in another interventional clinical study judged incompatible with this study.","18 Years",{"count":54,"type":22},2500,"OBSERVATIONAL","PAnDA-One is a prospective, multicenter, interventional study (10 centers, France) aimed at developing and validating a diagnostic support algorithm based on the ADx-One medical device, which non-invasively acquires thoracic vibrations using airborne ultrasound.\n\nThe study will enroll 2,500 patients presenting to the emergency department with acute dyspnea or non-traumatic chest pain, divided into a development cohort (N = 1,500) and an independent test cohort (N = 1,000). The deep learning algorithm will be trained to discriminate cardiovascular from non-cardiovascular origins of symptoms, and its performance will be assessed by AUROC, sensitivity, and specificity against a final diagnosis established by an expert adjudication committee.\n\nPatient management will not be modified by study participation.",[58,28],"Dyspnea",[60,61,62,63,64],"airborne ultrasound","dyspnea","chest pain","emergency department","algorithm","NOT_YET_RECRUITING","2026-06-15",{"date":68,"type":35},"2026-06-17",{"date":70,"type":22},"2026-09",{"date":72,"type":22},"2027-05",{"name":74,"class":75},"Austral Diagnostics","INDUSTRY",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":104,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":86,"type":22},1859,[25],"The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[90,91,92,93,94,95,28,96,97,98,99,100,101,102,103],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[105,106,107,108],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold",{"date":68,"type":35},{"date":111,"type":35},"2026-06-11",{"date":113,"type":22},"2033-06",{"name":115,"class":75},"Teleflex",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":125,"minAge":52,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":43},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820","NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)",true,"FEMALE","60 Years",{"count":128,"type":22},140,[130],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[133,134,135,136,137,28,138,139,140,141,142,143,144],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Activity, Motor","Healthy Aging","Weight, Body","Inflammation","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","2026-05-28",{"date":147,"type":35},"2026-06-02",{"date":149,"type":35},"2026-05-17",{"date":151,"type":22},"2029-09",{"name":153,"class":42},"University of Houston",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":43},"100637765","machine-learning-for-diagnosis-of-occlusive-mi-in-lbbb-patients-100637765","NCT07620119","Machine Learning for Diagnosis of Occlusive MI in LBBB Patients","Development of a Machine Learning Model for the Diagnosis of Occlusive Myocardial Infarction in the Setting of Left Bundle Branch Block","AI-LBBB","Inclusion Criteria:\n\n* Patients aged 18 years and older who present to the emergency department. Patients presenting with acute ischemic chest pain or clinical ischemia-equivalent symptoms (such as acute dyspnea, unexplained diaphoresis, or syncope).\n\nPatients with a confirmed Left Bundle Branch Block (LBBB) on their initial 12-lead electrocardiogram (ECG), which can be either newly developed or known\u002Fchronic.\n\nPatients who undergo invasive coronary angiography during their index hospital admission.\n\nPatients or their legally authorized representatives who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients under the age of 18. Pregnant or lactating women. Patients with poor-quality or uninterpretable digital ECG recordings due to severe artifact, missing leads, or technical errors.\n\nPatients who develop cardiopulmonary arrest before an initial diagnostic 12-lead ECG can be obtained in the emergency department.\n\nPatients transferred from another healthcare facility who have already undergone coronary angiography or revascularization.\n\nPatients who decline to participate or refuse to provide written informed consent.",{"count":163,"type":22},50,"This study investigates a new way to diagnose severe heart attacks in patients who have a specific electrical heart pattern called a Left Bundle Branch Block (LBBB). When patients present to the emergency department with chest pain, doctors routinely perform an electrocardiogram (ECG) to check for a heart attack. However, the presence of an LBBB can alter the heart's electrical signals on the ECG, effectively masking or hiding the typical signs of an ongoing acute coronary occlusion (a completely blocked artery). This making it highly challenging for emergency physicians to make an accurate and rapid diagnosis.\n\nThe primary purpose of this prospective and observational research is to develop and evaluate an artificial intelligence\u002Fmachine learning (ML) model that can analyze digital 12-lead ECG signals to accurately predict a true blocked coronary artery in patients with LBBB. The machine learning model will analyze raw digital ECG waveforms to detect subtle, microscopic patterns that might be missed by the human eye.\n\nTo confirm the accuracy of the model, its predictions will be compared directly with invasive coronary angiography results, which is the gold standard reference method used to visualize blocked vessels. Additionally, the study aims to evaluate if the model can differentiate between a true heart attack caused by a blocked artery (Type 1 MI) and other non-occlusive conditions that cause elevated heart enzymes (Type 2 MI). Ultimately, the investigators intend to determine whether integrating this machine learning tool into emergency care can safely reduce the rate of unnecessary emergency invasive procedures for patients who do not have a true coronary blockage.",[166,167,168,28,169],"Acute Myocardial Infarction (AMI)","Left Bundle Branch Block","Coronary Occlusion\u002FThrombosis","Myocardial Infarction","2026-05-22",{"date":147,"type":35},{"date":173,"type":22},"2026-06-01",{"date":175,"type":22},"2027-01-31",{"name":177,"class":42},"Konya City Hospital",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":43},"100611983","evaluation-and-optimization-of-telephone-triage-using-artificial-intelligence-ai-models-for-the-detection-of-demands-for-time-dependent-pathology-at-the-emergency-and-urgent-care-coordination-center-ccue-100611983","NCT07247669","Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).","Proyecto \"trIAje\": evaluación y optimización Del Triaje telefónico Mediante Modelos de Inteligencia Artificial (IA) Para la detección de Demandas Por patología Tiempo-dependiente en el Centro Coordinador de Urgencias y Emergencias (CCUE).","TrIAje Project","Inclusion Criteria:\n\nTelephone calls recorded with codes A36 + A58 (unconsciousness\u002Fcardiorespiratory arrest), A16 (respiratory distress), A23 (non-traumatic chest pain) and A54 (stroke).\n\nExclusion Criteria:\n\n* Demands with relevant information about the patient or the event incomplete or absent.",{"count":187,"type":22},5000000,"Improving Telephone Triage in Emergency Calls with AI The Coordinating Centre for Urgencies and Emergencies in Andalusia (CCUE) handles thousands of calls every day. Each call needs to be assessed based on the information given over the phone to determine how serious the case is. The reasons for calling range from minor health issues to life-threatening emergencies like cardiac arrest (CPA).\n\nThis project focuses on improving telephone triage for four key emergency situations that often indicate severe or life-threatening conditions:\n\nUnconsciousness \u002F Cardiac arrest Difficulty breathing Chest pain (non-traumatic, possible heart-related issues) Stroke symptoms Our goal is to make telephone triage more accurate and efficient by using advanced Artificial Intelligence (AI) techniques, including Machine Learning (ML) and Natural Language Processing (NLP). These tools will help CCUE operators make better and faster decisions, ensuring that patients receive the right care as quickly as possible.\n\nHow it will be done:\n\nThe investigators will analyze anonymized historical call data from the emergency coordination system (CCR) and digital clinical records (HCDM). This includes:\n\nStructured data: Predefined fields, such as answers to standard triage questions.\n\nUnstructured data: Free-text notes and other information recorded during the call.\n\nA hybrid AI approach will be used, combining:\n\nTraditional AI methods (supervised learning and deep learning) to classify cases.\n\nGenerative AI techniques (advanced language models) to extract useful insights from free-text data.\n\nBuilding the Best Prediction Model\n\nTo find the most effective AI model, we will test different machine learning techniques, including:\n\nDecision Trees Random Forests Support Vector Machines (SVM) XGBoost Ensemble methods Neural Networks We will also analyze which questions and variables are the most important in predicting the severity of a case. Based on this, we will suggest improvements to the current triage questions to enhance accuracy.\n\nMeasuring Success\n\nWe will evaluate the AI model using key performance metrics, including:\n\nAccuracy (overall correctness) Sensitivity (ability to detect real emergencies) Specificity (ability to avoid false alarms) False Positive \\& False Negative Rates (how often the system makes mistakes) Likelihood Ratios (how well the system distinguishes between urgent and non-urgent cases) F1-Score \\& ROC Curve (overall performance indicators) Why This Matters This project will assess how effective the current telephone triage system is and develop a new AI-powered model to improve it. The goal is to help emergency operators quickly identify the most serious cases, reducing response times and improving patient outcomes. In the future, the investigators aim to integrate this improved AI model into the CCUE system to enhance emergency response across Andalusia.",[28,190,191,192,193],"Stroke Acute","Respiratory Failure","Cardiac Arrest (CA)","Coma",[195,196,197,198,199,200],"Emergency Medical Communication Center","Triage Telephone","Emergency Medical Services","Priority","Machine Learning","Artificial Intelligence","2026-05-12",{"date":203,"type":35},"2026-05-13",{"date":205,"type":35},"2025-03-01",{"date":207,"type":22},"2027-12-31",{"name":209,"class":42},"Centro de Emergencias Sanitarias 061 Andalucía",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":43},"100527596","chest-pain-nurse-track-100527596","NCT06149819","Chest Pain Nurse Track","Nurse Pathway for the Diagnosis of Non-traumatic Chest Pain in the Emergency Department: Preliminary Pilot Study (Chest Pain Nurse Track)","CHESTNUT","Inclusion Criteria:\n\n* Admission to emergency department (ED) for non-traumatic Chest Pain\n* Affiliation to the French social security system\n* Written informed consent must be obtained\n* For women of childbearing age: effective contraception in place for at least 3 months. The absence of pregnancy should be confirmed by a negative urine test without delaying the start of the management including the realization of Electrocardiogram (EKG\u002FECG).\n\nExclusion Criteria:\n\n* Suspected alcohol, drug or toxic intoxication\n* Chest pain with associated neurological signs\n* Patient with pacemaker or defibrillator\n* Patient in vital distress requiring immediate medical intervention\n* Patient admitted with a previously established aetiological diagnosis\n* Unable to communicate or non-french speaking patients or those with impaired comprehension or consciousness\n* Pregnant or breast-feeding patients\n* Subject under administrative or judicial control, under protection",{"count":219,"type":22},182,[25],"Chest pain is a commonly encountered presentation in the emergency department (ED), with an incidence ranging from 5 to 12%. Chest pain has a wide range of aetiologies from the mildest to the most severe. In benign forms these pains can be musculoskeletal, psychogenic or even indeterminate (\\>60% depending on the place of recruitment). Coronary aetiology represents 12 to 25% of severe forms.\n\nThe management of chest pain in the emergency department is part of the daily life of nurses. According to the french 2020 Nurse Reception Organizer (IOA) guidelines, a nurse who has been trained for this role is required to \"triage\" (severity grade and orientation) patients presenting for this reason. The presence of specialized nurses in the management of chest pain allows faster initial management.\n\nTo date, no study has been conducted to assess the diagnostic and treatment performance of a nursing pathway for the management of patients presenting with acute chest pain regardless of the suspected diagnosis and not only acute coronary syndrome.",[28],[224,225,226,227],"non traumatic chest pain","Nurse","management","track","2026-04-14",{"date":230,"type":35},"2026-04-20",{"date":232,"type":35},"2023-12-14",{"date":234,"type":22},"2027-12-14",{"name":236,"class":42},"University Hospital, Grenoble",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":84,"enrollmentInfo":245,"targetDuration":247,"studyType":55,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100634226","triage-and-recognition-of-acute-aortic-dissection-in-chest-pain-by-electrocardiogram-artificial-intelligence-100634226","NCT07536932","Triage and Recognition of Acute Aortic Dissection in Chest Pain by Electrocardiogram-Artificial Intelligence","A Multicenter Prospective Study to Develop and Validate an Artificial Intelligence-Based Electrocardiogram Model for the Diagnosis of Acute Type A Aortic Dissection in Patients Presenting With Chest Pain","TRACE","Inclusion Criteria:\n\n* Male or female emergency department patients aged 18-80 years;\n* Clear presentation of chest pain or related chest\u002Fback pain;\n* Completion of standard 12-lead electrocardiography (ECG) within 24 hours after onset of chest pain;\n* ECG signal quality meeting the following criteria: QRS amplitude ≥ 0.1 mV and noise proportion \\\u003C 20%;\n* Availability of subsequent diagnostic workup confirming whether the patient had acute type A aortic dissection (TAAD) or another definitive diagnosis.\n\nExclusion Criteria:\n\n* Poor-quality ECG recordings, defined as missing leads in ≥ 3 leads or severe baseline instability;\n* Indeterminate final diagnosis;\n* History of prior surgery involving the aortic valve, aortic root, or ascending aorta.",{"count":246,"type":22},10000,"1 Day","The goal of this prospective multicenter observational study is to learn whether an artificial intelligence model based on electrocardiograms (ECGs) can help diagnose acute type A aortic dissection (TAAD) in adults who come to the emergency department with chest pain or related symptoms. The main question it aims to answer is:\n\nCan the AI-ECG model accurately distinguish TAAD from other causes of chest pain in a real-world emergency setting? Researchers will compare the AI model's ECG-based predictions with the final diagnosis confirmed by computed tomographic angiography (CTA), which is the reference standard. Participants will undergo routine emergency ECG testing and subsequent diagnostic evaluation as part of standard care. Clinical and ECG data will be collected from five tertiary hospitals, and the model's diagnostic performance will be assessed across centers.",[250,28],"Aortic Dissection Type A","2026-04-11",{"date":253,"type":35},"2026-04-17",{"date":255,"type":22},"2026-04",{"date":257,"type":22},"2026-12",{"name":259,"class":42},"Shanghai Zhongshan Hospital",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":268,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":284},"100508224","care-cp-testing-a-cardiovascular-ambulatory-rapid-evaluation-for-patients-with-chest-pain-100508224","NCT05897632","CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)","CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain )","CARE-CP","Inclusion Criteria:\n\n* Age ≥21 years old\n* Chest pain or Symptoms of acute coronary syndrome (ACS)\n* Moderate risk of ACS (all of the below)\n* Hear Score 4-6\n* Non-Ischemic electrocardiogram (ECG)\n* Two Troponin measures \\\u003C Sex-Specific Upper Reference Limit\n\n  * Women \\\u003C15 pg\u002Fml\n  * Men \\\u003C20 pg\u002Fml\n* No prior coronary artery disease (CAD)\n\n  * No Prior Myocardial Infarction (MI)\n  * No Prior Coronary Revascularization Procedures\n  * No Patients with ≥ 70% Obstructive Coronary Disease\n\nExclusion Criteria:\n\n* ST Elevation Myocardial Infarction (STEMI) Activation\n* ST Changes or new T-wave inversions ≥1mm on ECG\n* Any Elevated Troponin Measure (Based on Sex-Specific 99th Percentile)\n* Serial change between Troponin Measures (Delta) ≥5 pg\u002FmL\n* Stress Echocardiography, Nuclear Stress Test, Stress ECG, Stress Cardiac MRI, Coronary CT Angiogram (CCTA), Invasive Coronary Angiography (Cardiac Cath) within 1 year\n* \"Clean\" CCTA or Cardiac Cath (0% stenosis in all vessels) within the past 2 years\n* Chest Trauma\n* Pregnancy\n* Life Expectancy \\\u003C 1 year\n* Other comorbid conditions requiring hospitalization\n* Unstable Vitals (Blood Pressure \\\u003C90, Heart Rate \\>120 or \\\u003C50, O2 Sat \\\u003C90%)\n* End Stage Renal Disease; Dialysis or estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n* Transfers From Another Hospital\n* Non-English Speaking\n* Prisoners\n* Prior Enrollment\n* Already Enrolled in Other Interventional Trial","21 Years",{"count":270,"type":22},502,[25],"The goal of this study is to determine if rapid outpatient evaluation vs hospitalization management is the best strategy (based on patient-centered measures and safe, equitable, and efficient resource use) for evaluating patients with acute chest pain who are at moderate risk for acute coronary syndrome (ACS). Patients will be randomized in the Emergency Department to either an outpatient evaluation (CARE-CP) or hospitalization evaluation for their symptoms.",[28],[102,92],"2026-04-01",{"date":277,"type":35},"2026-04-06",{"date":279,"type":35},"2023-10-02",{"date":281,"type":22},"2027-09",{"name":283,"class":42},"Wake Forest University Health Sciences",3,{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":309,"locationsCount":43},"100603738","coronary-computed-tomographic-angiography-combined-with-ct-ffr-in-intermediate-risk-chest-pain-patients-100603738","NCT07140419","Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients.","A Prospective, Multicenter, Randomized Controlled Trial on the Impact of Coronary CTA Combined With CT-FFR on Diagnosis and Treatment Decisions and Clinical Outcomes in Emergency Patients With Intermediate Risk Chest Pain","E-CCTA","Inclusion Criteria:\n\n1. Age≥18 years；\n2. Within 24 hours of presenting to the emergency department (ED) with chest pain or other symptoms suggestive of coronary artery disease (CAD)；\n3. HEART-score \\>3 (according to http:\u002F\u002Fwww.heartscore.nl\u002F)；\n4. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Inability to obtain informed consent；\n2. Acute Coronary Syndromes (ACS) requiring urgent revascularization；\n3. Known Obstructive Coronary Artery Disease (CAD) or previous PCI or CABG;\n4. Concomitant severe congestive heart failure (New York Heart Association \\[NYHA\\] class III-IV or left ventricular ejection fraction \\[LVEF\\] \\\u003C 30%) or acute pulmonary edema;\n5. Severe hepatic insufficiency (Child-Pugh score ≥ C, or aspartate aminotransferase \\[AST\\] \\> 5× upper limit of normal); severe renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] ≤ 30 mL\u002Fmin\u002F1.73 m²) or patients receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis;\n6. History of prior coronary artery bypass grafting (CABG);\n7. Severe allergy to iodinated contrast agents;\n8. Inability to obtain high-quality imaging;\n9. Pregnant or lactating females;\n10. Concomitant diseases or limited life expectancy, quality of life, or functional status precluding further CAD evaluation;\n11. Any other factors that, in the investigator's judgment, make the patient unsuitable for study enrollment, completion of the study, or follow-up.",{"count":294,"type":22},2000,[25],"This study aims to investigate the guiding value of coronary CTA combined with CT-FFR in diagnostic and treatment decision-making for emergency chest pain patients at moderate risk, as well as its impact on clinical outcomes. Through a prospective multicenter randomized controlled trial, this research compares the preventive effects of early application of this technology versus standard care on major adverse cardiovascular and cerebrovascular events (MACCE), with the goal of optimizing the diagnostic and treatment processes for emergency chest pain patients.",[28,100,298],"Emergency Department",[300,298,301,302,100],"Intermediate Risk Chest Pain","CCTA","CT-FFR","2026-03-18",{"date":305,"type":35},"2026-03-20",{"date":275,"type":22},{"date":308,"type":22},"2032-06-30",{"name":310,"class":42},"Qilu Hospital of Shandong University",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":318,"minAge":319,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":43},"100626402","chest-ca-study-of-chest-pain-and-hidden-cardiac-amyloidosis-100626402","NCT07435168","CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis","CHEST-CA","Inclusion Criteria:\n\nNo signs of CAD through Rb-PET and\u002For CT coronary arteriogram\n\nExclusion Criteria:\n\nPrevious history of amyloidosis","MALE","65 Years",{"count":321,"type":22},300,[25],"The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD).\n\nPrior to inclusion, all patients will have undergone a CT coronary angiogram or an Rb-PET scan to rule out the possibility of CAD.\n\nParticipants will be subject to several examinations, including blood tests, urine samples, ECG, echocardiography, and bone scintigraphy. An endomyocardial biopsy may be conducted if necessary.",[325,28],"Cardiac Amyloidosis","2026-02-25",{"date":328,"type":35},"2026-02-27",{"date":330,"type":35},"2024-04-01",{"date":332,"type":22},"2027-04-01",{"name":334,"class":42},"Rigshospitalet, Denmark",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":124,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":43},"100536230","virtual-reality-for-non-cardiac-chest-pain-100536230","NCT06262126","Virtual Reality for Non-cardiac Chest Pain","A Feasibility Study of Virtual Reality for the Treatment of Non-cardiac Chest Pain","Inclusion Criteria:\n\n* Symptoms of non-cardiac chest pain (recurrent anginal-like or atypical chest pain)\n* Negative prior cardiac evaluation (at a minimum, including electrocardiogram)\n* Prior esophagogastroduodenoscopy and\u002For barium esophagram to rule out severe esophagitis, stricture, or motility abnormality\n\nExclusion Criteria:\n\n* Initiation of a proton pump inhibitor (PPI) within 8 weeks\n* Major concomitant illness\n* Current drug or alcohol use that that would interfere with adherence to study requirements\n* Symptoms of vertigo or dizziness that would limit tolerability of the VR headset",{"count":343,"type":22},10,[25],"The purpose of this study is to determine if virtual reality (VR) will improve symptoms in non-cardiac chest pain (NCCP).",[347,28],"Gastrointestinal Diseases",[349],"Virtual reality","2026-02-10",{"date":352,"type":35},"2026-02-12",{"date":354,"type":35},"2024-02-14",{"date":356,"type":22},"2026-12-31",{"name":358,"class":42},"Mayo Clinic",{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":366,"targetDuration":367,"studyType":55,"phases":4,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":43},"100531170","early-warning-and-classification-model-for-acute-non-traumatic-chest-pain-100531170","NCT06196307","Early Warning and Classification Model for Acute Non-traumatic Chest Pain","A Prospective Study of Acute Nontraumatic Chest Pain - Warning and Classification","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Symptom onset or worsening within 24 hours before presentation, with a chief complaint of acute chest pain meeting the broad definition of chest pain (2021 AHA)\n3. Presentation to the emergency department, with a clinical diagnosis consistent with non-traumatic chest pain\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. traumatic chest pain\n2. systemic pain caused by malignant tumors or rheumatic diseases involving the chest\n3. Patients were lost to follow-up",{"count":246,"type":22},"1 Month","Acute non-traumatic chest pain is one of the common causes of presentation in emergency patients, but the causes of acute non-traumatic chest pain are complex, the severity of the condition varies greatly, and the specificity of symptoms is not high. Machine learning and intelligent auxiliary models can greatly shorten the time of clinical decision-making, and improve the accuracy of etiological diagnosis in patients with chest pain, reduce the rate of misdiagnosis and missed diagnosis, and provide a clear direction for further treatment.",[28],"2026-02-03",{"date":372,"type":35},"2026-02-05",{"date":374,"type":35},"2022-08-30",{"date":376,"type":22},"2028-12-30",{"name":378,"class":42},"Xiao-nan He",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":397,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100581693","one-hour-troponin-using-a-high-sensitivity-point-of-care-assay-in-emergency-primary-care-100581693","NCT06853626","One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care","Improved Management of Acute Chest Pain in Emergency Primary Care. The OUT-POC Study (One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care)","OUT-POC","Inclusion Criteria:\n\n* Patients (18+ years) with non-traumatic acute chest pain presenting in emergency primary care\n* Troponin testing requested by the treating physician\n\nExclusion Criteria:\n\n* Acute STEMI (direct hospital referral required)\n* Haemodynamically unstable (direct hospital referral required)\n* Not able to provide written, informed consent (i.e., due to time restraints, language barriers, impaired cognitive function, or other reasons)",{"count":54,"type":22},[25],"Acute chest pain is a prevalent medical emergency in primary emergency care settings. Triage of chest pain prior to hospital admission presents significant challenges due to the absence of sufficiently sensitive diagnostic tools. Clinical signs, symptoms, risk assessment scores, or a normal electrocardiogram (ECG) can reliably exclude acute myocardial infarction (MI). This diagnostic uncertainty has resulted in chest pain being the second most common cause for acute hospital referrals from Norwegian emergency primary care, even though chest pain is frequently non-cardiac in origin.\n\nIn acute MI events, cardiac troponins are released into the bloodstream from the damaged myocardium, where low values are used to exclude MI. Until recently, such testing has necessitated using high-sensitivity cardiac troponin (hs-cTn) assays, which have been limited to hospital laboratories. However, recent technological advancements in point-of-care (POC) testing allow access to whole-blood assays that meet high-sensitivity criteria.\n\nIn this upcoming project, the investigators will evaluate the implementation of a whole-blood POC assay (QuidelOrtho TriageTrue hs-cTnI) across six Norwegian emergency primary care clinics. The study plans to enrol 2,500 patients over a period of 1.5 years. The clinical performance of the novel strategy will be investigated, as well as its impact on healthcare utilization and hospital referrals compared to standard care. Additionally, the investigators will assess the prevalence of persistent chest pain and its effects on quality of life, alongside psychological stress and anxiety, through validated questionnaires.\n\nThis project aims to offer better and more comprehensive management of the large group of emergency primary care patients with acute chest pain, contributing to reduced hospital referrals, improved quality of life, and more sustainable use of healthcare services.",[166,28,391,392,393,394,395,396],"Acute Coronary Syndromes (ACS)","Non-cardiac Chest Pain","Troponin","Point of Care Testing","Out-of-hours Medical Care","Primary Care",[398,399,400,401,402,62,403,404,405,406,407,385,408],"TriageTrue","POC","hs-cTnI","0\u002F1-hour algorithm","troponin","primary care","OOH","out-of-hours","acute myocardial infarction","point-of-care","QuidelOrtho","2025-12-09",{"date":411,"type":35},"2025-12-10",{"date":413,"type":35},"2025-06-27",{"date":415,"type":22},"2029-12-31",{"name":417,"class":42},"University of Oslo",6,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":43},"100611059","ai-assisted-interpretation-of-cardiac-ct-in-the-emergency-department-100611059","NCT07235657","AI-Assisted Interpretation of Cardiac CT in the Emergency Department","Evaluation of the Impact of AI-Based Cardiac CT Interpretation Tool on Emergency Physicians' Decision-Making","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients presenting to the emergency department with chest pain\n* Patients assessed as intermediate risk (Heart Score 4-6)\n\nExclusion Criteria:\n\n* Prior history of coronary revascularization (coronary artery bypass graft surgery or stent placement)\n* Presence of intracardiac metallic devices such as pacemaker or prosthetic heart valves\n* Contraindications to contrast media (e.g., contrast allergy, severe renal impairment with eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Patients unable to cooperate (e.g., severe anxiety, non-cooperation)",{"count":427,"type":22},530,[25],"\" This prospective, pragmatic, randomized controlled trial is designed to evaluate the impact of an artificial intelligence (AI)-based coronary computed tomography angiography (CCTA) interpretation tool (Angiomics) on emergency physicians' diagnostic performance and clinical decision-making in patients presenting with acute chest pain.\n\nCCTA is a critical diagnostic modality for suspected acute coronary syndrome (ACS) in the emergency department (ED). Accurate interpretation often requires experienced radiologists, who may not always be available, particularly during off-hours. The introduction of AI-based interpretation tools into clinical workflow has the potential to enhance diagnostic accuracy, increase physician confidence, reduce delays in decision-making, and improve efficiency of resource utilization. However, evidence regarding the real-world effectiveness of such AI tools in the ED setting remains limited.\n\nEligible participants will include adults aged 18 years or older presenting to the ED with chest pain and classified as intermediate risk (HEART score 4-6). Participants will be randomized into two groups: (1) AI-assisted CCTA interpretation, in which emergency physicians interpret scans with access to AI results; and (2) standard interpretation, in which emergency physicians interpret CCTA without AI support. In both groups, physicians will document the presence of stenosis in the four major coronary arteries (LM, LAD, LCX, RCA) and report diagnostic confidence on a 5-point Likert scale.\n\nThe primary outcome is the negative predictive value (NPV) of CCTA interpretation at the patient level, comparing AI-assisted versus standard interpretations against the reference standard of blinded consensus readings by board-certified radiologists. Secondary outcomes include sensitivity, specificity, positive predictive value (PPV), accuracy, diagnostic confidence, vessel-level diagnostic performance, and agreement with radiologist consensus using Cohen's Kappa.\n\nThe study aims to enroll approximately 530 participants (276 in the control arm and 254 in the intervention arm, accounting for an expected 10% dropout). Enrollment and follow-up will be conducted at Severance Hospital and Gangnam Severance Hospital over a 24-month period following IRB approval. The results are expected to provide evidence for the clinical utility and effectiveness of AI-based CCTA interpretation in the ED and to guide integration of AI into emergency care in order to optimize patient outcomes and healthcare efficiency.",[28,102,100],[200,432,433],"Emergency Service, Hospital","Coronary Computed Tomography Angiography","2025-11-14",{"date":436,"type":35},"2025-11-19",{"date":438,"type":22},"2025-11",{"date":440,"type":22},"2027-08",{"name":442,"class":42},"Yonsei University",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":43},"100542900","clinical-evaluation-of-radiation-reduction-for-optimized-safety-100542900","NCT06348875","Clinical Evaluation of Radiation Reduction for Optimized Safety","CERROS","Inclusion Criteria:\n\n* Referred for clinically indicated coronary angiography\n* ≥18 years of age\n* Not pregnant\n* English speaking\n* Not imprisoned\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamically or electrically unstable.\n* Indication for coronary angiography is emergent, including ST-segment elevation myocardial infarction\n* History of coronary artery bypass grafting\n* An eGFR \\\u003C60\n* Pregnant or lactating\n* A BMI of 45 or greater\n* Any other factor that the investigator feels would put the patient at increased risk or otherwise make the patient unsuitable for participation in the protocol",{"count":163,"type":22},"The primary objective of this study is to determine whether a reduced radiation protocol (RRP) in which angiograms are acquired at ultralow radiation doses and then processed using spatiotemporal enhancement software can produce similar quality angiographic images as compared with standard techniques.",[100,169,90,453,103,28],"Coronary Stenosis","2025-11-12",{"date":456,"type":35},"2025-11-13",{"date":458,"type":22},"2026-02-15",{"date":460,"type":22},"2026-07-15",{"name":462,"class":75},"Angiowave Imaging",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":124,"sex":17,"minAge":52,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":43},"100508162","magnetocardiography-in-the-accurate-identification-of-myocardial-infarction-100508162","NCT05896826","Magnetocardiography in the Accurate Identification of Myocardial Infarction","Ultra-sensitive Magnetocardiography in the Accurate Identification of Myocardial Infarction","For healthy volunteers:\n\nInclusion Criteria:\n\n1. Age 18-79 years old;\n2. No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included;\n3. The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included).\n4. Sign the informed consent.\n\nExclusion Criteria:\n\n1. Those who with acute or chronic respiratory diseases;\n2. Those who with obvious abnormality of liver or kidney function;\n3. Those who with endocrine diseases such as abnormal thyroid function;\n4. Those who with anemia or other blood diseases;\n5. Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.);\n6. Those who are obese (BMI\\>30kg\u002Fcm2) or underweight (BMI\\\u003C18kg\u002Fcm2);\n7. Those who with malignant tumors;\n8. Those who with infectious diseases or infectious diseases;\n9. Those who with trauma or physical disability;\n10. Those who with psychological or mental illness such as depression;\n11. Those who are professional athletes, pregnant or breastfeeding women, alcoholics;\n12. Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination;\n13. Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.\n\nFor chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination:\n\nInclusion Criteria:\n\n1. Age 18-79 years old;\n2. Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography);\n3. Sign the informed consent.\n\nExclusion Criteria:\n\n1. Patients with known structural heart disease such as cardiomyopathy and valvular disease;\n2. Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;\n3. History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;\n4. Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;\n5. Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;\n6. Obese (BMI\\>30kg\u002Fcm2) or underweight (BMI\\\u003C18kg\u002Fcm2);\n7. Patients with malignant tumors;\n8. Professional athletes, pregnant or breastfeeding women, alcoholics;\n9. Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;\n10. Patients with infectious diseases or infectious diseases;\n11. Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;\n12. Unable to or fail to cooperate with the corresponding research requirements.","79 Years",{"count":472,"type":22},3841,"Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial infarction. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect myocardial infarction. Myocardial infarction are diagnosed by electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography). Myocardial infarction is also quantified by cardiac magnetic resonance or single-photon-emission tomography. Healthy volunteers and chest pain patients who will receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography) examination will be enrolled in this study.",[28,102,169],"2025-09-27",{"date":477,"type":35},"2025-10-02",{"date":479,"type":35},"2023-06-01",{"date":481,"type":22},"2026-12-01",{"name":310,"class":42},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":490,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":496,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":43},"100607777","ecg-less-coronary-computed-tomography-angiography-in-the-management-of-patients-presenting-with-high-troponin-chest-pain-100607777","NCT07192965","ECG-less Coronary Computed Tomography Angiography in the Management of Patients Presenting With High-troponin Chest Pain","ECLECTIC","Inclusion Criteria:\n\n* Age ≥ 30 years old\n* Admission at the ER with acute chest pain and at least one of the follow-ing:\n\n  1. ECG abnormality;\n  2. positive rule-in criteria according to the ESC guidelines (hs-cTnT ≥ 52 in at least one assay or 1h ∆ ≥ 5);\n  3. troponine value in the \"observe pathway\" (hs-cTnT ≥ 12 in at least one assay or 1h ∆ ≥ 3) AND a high clinical suspicion of MI.\n\nExclusion Criteria:\n\n* Indication for urgent ICA (ST-elevation, hemodynamic or electric instabil-ity, refractory chest pain, mechanical complications)\n* eGFR \\\u003C 30 ml\u002Fmin\n* Previous coronary stenting\n* Previous CABG\n* Recent ACS within 6 months\n* Known severely reduced ejection fraction (EF \\\u003C 30%)\n* Contrast allergy\n* Inability to provide informed consent\n* Limited life expectancy \\\u003C 2 years due to non-cardiac conditions\n* Pregnant and breast-feeding women\n* Known congenital heart disease\n* Atrial fibrillation","30 Years",{"count":492,"type":22},230,[25],"Chest pain represents a common reason for consultation to emergency room. This symptom can be explained by a broad spectrum of conditions, from benign musculoskeletal or esophageal pain to life-threatening disease such as aortic dissection, pulmonary embolism, and myocardial infarction.\n\nThere are already different diagnostic tools to quickly identify most dangerous diseases, for example electrocardiogram, blood samples with specific markers of cardiac injury, chest X-ray and echography. In case a doubt of disease is raised after the first clinical evaluation, it is possible to proceed with more complex, expensive and invasive examinations, namely a computed tomography (CT) scan or an invasive coronary angiography (ICA).\n\nCT scan allows the diagnosis of various conditions such as pleural, pulmonary, pericardial and vascular disease such as pneumonia, pneumothorax, pleural and pericardial fluid, pulmonary embolism (PE), acute aortic dissection (AOD). In order to see the pulmonary, aortic and coronary arteries, a contrast injection is needed. Moreover, since the heart and the aortic root are continuously moving, specific technical measures to obtain good quality images are needed.\n\nRecently, a new CT scan system has been developed. It allows to obtain good quality images of the heart and aortic root using an estimated heart rhythm, without ECG-gating. This allows to perform a CT scan of the heart in a reduced amount of time, and without need for controlling heart rate. Moreover, it is possible to obtain information on both aortic, coronary, and pulmonary artery with the same contrast injection. This may be of great interest in the context of patients presenting at the emergency room with chest pain and with a suspicion of pulmonary embolism, myocardial infarction, or aortic dissection, since with a single fast exam it is possible to rule out all these conditions.\n\nCoronary arteries are very small vessels, and the accuracy of this new technique in identifying a significant obstruction is still to be proved. At present, patients with chest pain and a suspicion of myocardial infarction undergo an invasive coronary angiography. If this new tool proves to be reliable, it will be possible to reduce the number of useless invasive examination in patients in which the presence of coronary artery disease (CAD) is ruled-out. In addition, the CT scan can help quickly and effectively plan treatment when worrying abnormalities are detected in the coronary arteries that are associated with a higher risk.\n\nTherefore, this clinical trial (further on referred to as \"trial\") will evaluate the investigational medicinal product (IMP), ECG-less Revolution Apex Elite system (GE Healthcare, Waukesha, WI -USA) for the diagnosis of coronary artery disease. The purpose of this trial is to learn about: the accuracy of this new CT system compared to the gold standard invasive coronary angiography in diagnosing coronary artery disease. The number of patients receiving an alternative diagnosis such as pulmonary embolism, aortic dissection, pulmonary, pleural or pericardial disease will be evaluated. Finally, the prognostic predictive value of the CT compared with ICA, in predicting myocardial infarction, coronary revascularization, and cardiac death at a follow-up of 18 months will be assessed. Patient will undergo a computer tomography examination with this new technique, evaluating both pulmonary, aortic, and coronary arteries. Then, as indicated by current guidelines, they will undergo an invasive coronary angiography.",[28,391],[497,498,499,500,501],"Chest pain","Acute coronary syndrome","NSTEMI","ECG-less coronary computed tomography angiography","ECG-les CCTA","2025-09-23",{"date":504,"type":35},"2025-09-25",{"date":506,"type":35},"2025-09-10",{"date":508,"type":22},"2028-03",{"name":510,"class":42},"Universitair Ziekenhuis Brussel",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":533},"100449964","the-orchestrate-myocarditis-registry-100449964","NCT05139329","The ORCHESTRATE-Myocarditis Registry","Observational Registry of Ischemia Negative Chest Pain as the Presentation of Underlying Myocarditis: the ORCHESTRATE-Myocarditis Registry","Inclusion criteria\n\n1. Age \\>18 years\n2. Patients with a presentation of typical or atypical chest pain (ICD-10 Code R07.89, R07. 9)\n3. Patients with a negative ischemic workup: (including Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography showing anything greater than \"non-obstructive CAD\")\n\nExclusion criteria\n\n1. Patients with any evidence of positive ischemic workup as the cause of typical\u002Fatypical chest pain (as seen on Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography)\n2. Previously documented history of Prinzmetal angina or coronary vasospasm\n3. History of prior myocardial infarction\n4. History of any prior CAD with severity greater than \"non-obstructive CAD\" in all 3 coronary arteries\n5. History of LVEF\\\u003C40%\n6. Previously documented history of pericarditis\n7. Previously documented history of costochondritis",{"count":519,"type":22},382,"A retrospective, observational study consisting of patients who presents with typical\u002Fatypical chest pain and have an ensuing negative ischemic evaluation",[522,523,28],"Myocarditis","Ischemia","2025-08-27",{"date":526,"type":35},"2025-08-28",{"date":528,"type":22},"2026-01",{"date":530,"type":22},"2026-05",{"name":532,"class":42},"Kansas City Heart Rhythm Research Foundation",4,{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":542,"targetDuration":543,"studyType":55,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":43},"100119623","evaluation-of-patients-with-non-obstructive-coronary-arteries-100119623","NCT00823563","Evaluation of Patients With Non-obstructive Coronary Arteries","Evaluation of Patients With Angina in the Absence of Obstructive Coronary Artery Disease","noCAD","Inclusion Criteria:\n\n1. Patient referred for elective coronary angiography because of a reasonable clinical suspicion of coronary ischemia.\n2. Presence of angina or an anginal equivalent (including chest, back, shoulder, arm, neck, jaw discomfort, or shortness of breath brought on by physical exertion, emotional stress, or certain times of day\u002Fmonth).\n\nExclusion Criteria:\n\n1. Asymptomatic (such as a pre-op cath)\n2. Status-post heart transplant\n3. Age \\\u003C18\n4. Renal insufficiency (creatinine \\>1.5)\n5. Presence of an acute coronary syndrome (STEMI or NSTEMI), Tako-tsubo, an abnormal ejection fraction (EF\\\u003C55%), cardiogenic shock, or recent VT\u002FVF\n6. Presence of another likely explanation of chest pain, such as pulmonary hypertension or aortic stenosis\n7. History of adverse reaction to any of the medications being used (acetylcholine, nitroglycerin, adenosine, or heparin)\n8. Currently taking vasoactive medication (such as nitroglycerin)\n9. Inability to provide an informed consent, including an inability to speak, read, or understand English, Spanish, Chinese, Farsi, Japanese, Korean, Russian, or Vietnamese\n10. A hearing impairment that won't allow for a typical verbal conversation or a visual impairment that won't allow for reading of the written consent\n11. Participation in another study (with the exception of the Stanford Gene-PAD study)\n12. A potentially vulnerable subject (including minors, pregnant women, economically and educationally disadvantaged, decisionally impaired, and homeless people)",{"count":294,"type":22},"15 Years","Patients with angina and non-obstructive CAD are common within clinical practice, but remain a challenge with regard to diagnosis and treatment. When these patients undergo a comprehensive evaluation at the time of invasive coronary angiography, occult coronary abnormalities are frequently found. We hope to learn the overall prevalence and presentation of these occult coronary abnormalities and its long term outcome in this patient population.",[28,523],"2025-06-02",{"date":548,"type":35},"2025-06-05",{"date":550,"type":35},"2007-06",{"date":552,"type":22},"2047-06",{"name":554,"class":42},"Stanford University",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":43},"100567636","myocardial-perfusion-quantification-with-spect-using-multi-pinhole-collimator-compared-to-photon-counting-coronary-cta-100567636","NCT06670768","Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","Myocardial Perfusion Quantification With Single Photon Emission Computed Tomography Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary Computed Tomography Angiography","MY-FUSION","Inclusion Criteria:\n\n* suspected coronary artery disease\n* referred to coronary CTA or SPECT MPI by the patient's physician\n* agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)\n* suitable for informed consent\n\nExclusion Criteria:\n\n* moderate or severe aortic valve stenosis\n* atrial fibrillation\n* pregnancy or breastfeeding\n* history of coronary artery bypass graft implantation\n* history of stent implantation\n* chronic renal failure (eGFR \\\u003C 30 ml\u002Fm2)\n* active oncological treatment\n* congenital heart disease\n* left or right bundle branch block",{"count":163,"type":22},[25],"This prospective study aims to compare functional abnormalities detected using myocardial perfusion SPECT imaging (MPI SPECT) with the extent and severity of anatomical findings on coronary computed tomography angiography (coronary CTA). Additionally, the investigators aim to enhance the diagnostic value of MPI SPECT by quantifying myocardial blood flow and utilizing myocardial flow reserve calculated from dynamic SPECT images.\n\n50 patients with suspected coronary artery disease are anticipated to be enrolled. Pharmacological stress and rest-phase dynamic and static MPI SPECT following an additional coronary CTA scan are to be performed. The obtained multimodality imaging data (functional and anatomical parameters) are planned to be compared and subjected to statistical analysis. The results of this study are expected to improve risk assessment for patients with moderate cardiovascular risk and enhance the diagnostic performance of MPI SPECT.",[100,433,567,91,92,93,101,90,28],"SPECT",[569,570,571,572,573],"Coronary Artery Disease,","Myocardial Perfusion Imaging","Myocardial Perfusion Imaging Absolute Quantification","Myocardial Flow Reserve","Plaque volume","2025-04-24",{"date":576,"type":35},"2025-04-25",{"date":578,"type":35},"2024-03-06",{"date":580,"type":22},"2026-08-30",{"name":582,"class":42},"Semmelweis University",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":284},"100582108","validation-of-the-har-score-for-prioritization-of-patients-calling-the-emergency-medical-service-for-chest-pain-by-emergency-call-dispatcher-100582108","NCT06859021","Validation of the HAR Score for Prioritization of Patients Calling the Emergency Medical Service for Chest Pain by Emergency Call Dispatcher","Validation of the HAR Score for Prioritization of Patients Calling the Emergency Medical Service for Chest Pain by Emergency Call Dispatcher : Reg-HAR Study","Reg-HAR","Inclusion Criteria:\n\n* Patient of legal age (≥ 18 years)\n* Calling Center 15 from 49, 72 or 37\n* Expressing non-traumatic chest pain, even if this is not the main reason for seeking help.\n\nExclusion Criteria:\n\n* Treatment in departments other than 49, 72 and 37\n* Taken in charge in an emergency department of a private facility in the 49, 72 and 37 départements\n* Poor understanding of the French language\n* Non-affiliated or non-beneficiary of a social security scheme\n* Person deprived of liberty by judicial or administrative decision\n* Person under forced psychiatric care\n* Person subject to a legal protection measure\n* Person unable to express his\u002Fher non-opposition.\n* Follow-up at Day 30 impossible for any reason\n* Person having expressed his\u002Fher opposition to the collection of his\u002Fher data.",{"count":592,"type":22},796,"The lifetime prevalence of chest pain in the general population is 20-40%. The etiologies to be evoked from the outset of management are those of cardiovascular origin, such as acute coronary syndrome (ACS) and pulmonary embolism. ACS is responsible for almost 20% of deaths. Delay in treatment is a major prognostic factor, given the importance of coronary reperfusion.\n\nIn France, one of the first contacts with the healthcare system is the medical regulation assistant (MRA) at the Centre 15. His or her role is to prioritize the call according to the identification of immediate signs of seriousness, and if necessary, to decide autonomously to send a rescue team before medical regulation. Depending on the reason for the call and any signs of seriousness, it prioritizes the call according to the expected response time. In line with current recommendations, all calls for chest pain should be answered by an emergency medical dispatcher (EMR) within 5 minutes. However, 60-90% of chest pain calls are not of cardiovascular origin. Their prioritization could therefore be re-qualified for longer response times.\n\nGiven the frequency of this type of call, a more efficient MRA referral strategy is needed. To achieve this, decision-support tools would be essential.\n\nThe performance of the HAR (History, Age and Risk Factors) score has been recently explored, derived from the HEART score, in a previous single-center prospective study in 2019. It stratifies the risk of a major cardiovascular event (MCE) into low (0 or 1 point), intermediate (2 or 3 points) or high (4, 5 or 6 points).\n\nInvestigator's hypothesis is that the HAR score could be entrusted to MRA, to enable them to optimize the prioritization of patients calling with non-traumatic chest pain, by qualifying low-risk chest pain calls on the one hand, which could be prioritized in P2 SNP, and high-risk calls on the other, making it possible to anticipate the dispatch of an emergency service.",[28],[596,597,598],"Chestpain","HAR score","Emergency call","2025-03-19",{"date":601,"type":35},"2025-03-24",{"date":603,"type":22},"2025-05-02",{"date":605,"type":22},"2025-12",{"name":607,"class":42},"Centre Hospitalier le Mans",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":43},"100571293","chest-pain-symptoms-differences-between-diabetic-patients-and-non-100571293","NCT06718374","Chest Pain Symptoms Differences Between Diabetic Patients and Non","Chest Pain Symptoms Differences Between Diabetes Mellitus and Non-diabetes Mellitus Patients with Acute Coronary Syndrome","chestpaindm","Inclusion Criteria:\n\ni) Patients diagnosed with STEMI and NSTEMI ii) Both genders iii) above the age of 30 years iv) Patients with acute myocardial infarction with or without chest pain (angina) for 24 hours v) patients who are hemodynamically stable vi) patients without acute decompensated heart failure (ADHF) vii) patients without malignant arrhythmias viii) patients without in Acute Lung Oedem (ALO) condition ix) patients not using ventilator x) patient willing to and become respondents.\n\nExclusion Criteria:\n\ni) Patients with several complications, thereby making it impossible to interview them ii) patients who have never undergone CABG surgery iii) patients who refuse to be respondents",{"count":163,"type":22},"Cardiovascular disease is the most severe cause of death among all non-infectious diseases and accountable for 17.5 million deaths in the world. Heart mortality in patients with DM is frequently associated with prevalence silent ischemia, which is triggered by autonomic neuropathy, thereby decreasing the chest pain felt by them",[28,619],"Diabetes Mellitus","2024-12-04",{"date":622,"type":35},"2024-12-06",{"date":624,"type":22},"2025-01-10",{"date":626,"type":22},"2026-06",{"name":628,"class":42},"Assiut University",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":637,"conditions":638,"keywords":639,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":43},"100569347","impact-of-general-practice-follow-up-on-emergency-hospitalization-of-patients-admitted-for-chest-pain-100569347","NCT06693063","Impact of General Practice Follow-up on Emergency Hospitalization of Patients Admitted for Chest Pain","Inclusion Criteria:\n\n* Patient admitted to Emile Roux hospital emergency department with chest pain\n* Patient affiliated to the Social security system\n* Patient able to give informed non-opposition to participating in research\n\nExclusion Criteria:\n\n* Patient under guardianship, curatorship, safeguard of justice or prisoners\n* Patient with cognitive disorders\n* Pregnant or breast-feeding women\n* Refusal to participate",{"count":636,"type":22},100,"This is a prospective observational study carried out in the emergency department of Emile Roux Hospital. Its aim is to compare the medical, psychological and social characteristics of patients followed up by a general practitioner and those without regular follow-up, using an anonymous questionnaire completed by the general practitioner in the emergency department, for patients consulting for the reason \"chest pain\".",[28],[640,641],"emergency admission","general practitioner","2024-11-15",{"date":644,"type":35},"2024-11-18",{"date":646,"type":35},"2024-10-14",{"date":648,"type":22},"2025-07",{"name":650,"class":42},"Centre Hospitalier Emile Roux",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":43},"100567568","use-of-determine-learning-based-cardiodynamicsgram-cdg-for-rapid-and-precise-stratification-of-chest-pain-in-emergency-department-100567568","NCT06669884","Use of Determine Learning-based Cardiodynamicsgram (CDG) for Rapid and Precise Stratification of Chest Pain in Emergency Department","Inclusion Criteria:\n\n* aged 18 years or older\n* Those with suspected ACS who have symptoms of acute chest pain, visiting in the emergency department\n\nExclusion Criteria:\n\n* Those who diagnosed with ST-segment elevation myocardial infarction (STEMI)\n* Those with hemodynamic instability (cardiogenic shock, cardiac arrest)\n* Those with malignant arrhythmias(ventricular tachycardia, ventricular fibrillation, third-degree atrioventricular block)\n* Those with aortic coarctation, or acute pulmonary embolism\n* Those who has an unanalysable ECG report due to loosened leads, unstable baseline, or signal interference, etc.",{"count":658,"type":22},8000,"Chest pain accounts for 10-20 percent of all emergency department visits. The stratification of chest pain is always a challenge. Electrocardiograms (ECG) have been used in clinical practice for 100 years, which is too important to be replaced due to its advantages of non-invasive, simple, rapid and inexpensive. ECG contains numerous signals derived from depolarization and repolarization of cardiomyocytes. However, the interpretation of ECG hasn't improved much in a hundred years. Based on determine-learning, Cong W's team developed an technique called \"cardiodynamicsgram (CDG)\", which is an outstanding method to identify myocardial ischemia. This study will further investigate the accuracy of CDG in stratification of patients with chest pain in Emergency department.",[28,102],"2024-11-07",{"date":663,"type":35},"2024-11-12",{"date":665,"type":35},"2021-10-28",{"date":667,"type":22},"2024-10-31",{"name":310,"class":42}]